Literature DB >> 24990071

International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading.

David N Louis1, Arie Perry, Peter Burger, David W Ellison, Guido Reifenberger, Andreas von Deimling, Kenneth Aldape, Daniel Brat, V Peter Collins, Charles Eberhart, Dominique Figarella-Branger, Gregory N Fuller, Felice Giangaspero, Caterina Giannini, Cynthia Hawkins, Paul Kleihues, Andrey Korshunov, Johan M Kros, M Beatriz Lopes, Ho-Keung Ng, Hiroko Ohgaki, Werner Paulus, Torsten Pietsch, Marc Rosenblum, Elisabeth Rushing, Figen Soylemezoglu, Otmar Wiestler, Pieter Wesseling.   

Abstract

Major discoveries in the biology of nervous system tumors have raised the question of how non-histological data such as molecular information can be incorporated into the next World Health Organization (WHO) classification of central nervous system tumors. To address this question, a meeting of neuropathologists with expertise in molecular diagnosis was held in Haarlem, the Netherlands, under the sponsorship of the International Society of Neuropathology (ISN). Prior to the meeting, participants solicited input from clinical colleagues in diverse neuro-oncological specialties. The present "white paper" catalogs the recommendations of the meeting, at which a consensus was reached that incorporation of molecular information into the next WHO classification should follow a set of provided "ISN-Haarlem" guidelines. Salient recommendations include that (i) diagnostic entities should be defined as narrowly as possible to optimize interobserver reproducibility, clinicopathological predictions and therapeutic planning; (ii) diagnoses should be "layered" with histologic classification, WHO grade and molecular information listed below an "integrated diagnosis"; (iii) determinations should be made for each tumor entity as to whether molecular information is required, suggested or not needed for its definition; (iv) some pediatric entities should be separated from their adult counterparts; (v) input for guiding decisions regarding tumor classification should be solicited from experts in complementary disciplines of neuro-oncology; and (iv) entity-specific molecular testing and reporting formats should be followed in diagnostic reports. It is hoped that these guidelines will facilitate the forthcoming update of the fourth edition of the WHO classification of central nervous system tumors.
© 2014 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.

Entities:  

Keywords:  Astrocytoma; World Health Organization; atypical teratoid rhabdoid tumor; brain tumors; classification; glioblastoma; glioma; grading; medulloblastoma; oligodendroglioma

Mesh:

Year:  2014        PMID: 24990071     DOI: 10.1111/bpa.12171

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  209 in total

1.  Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours.

Authors:  Ji Xiong; Wenli Tan; Jianbo Wen; Jiawei Pan; Yin Wang; Jun Zhang; Daoying Geng
Journal:  Eur Radiol       Date:  2015-09-22       Impact factor: 5.315

Review 2.  The evolving molecular genetics of low-grade glioma.

Authors:  Sriram Venneti; Jason T Huse
Journal:  Adv Anat Pathol       Date:  2015-03       Impact factor: 3.875

3.  Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution.

Authors:  Federico Pessina; Pierina Navarria; Luca Cozzi; Stefano Tomatis; Elena Clerici; Anna Maria Ascolese; Matteo Simonelli; Matteo Perrino; Marco Riva; Marco Rossi; Roberta Rudà; Armando Santoro; Lorenzo Bello; Marta Scorsetti
Journal:  CNS Oncol       Date:  2017-07-18

4.  Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000-2008.

Authors:  Y Yuan; J Ross; Q Shi; F G Davis
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

5.  REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells.

Authors:  Anantha L Marisetty; Sanjay K Singh; Tran N Nguyen; Cristian Coarfa; Bin Liu; Sadhan Majumder
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

6.  Analysis of immunobiologic markers in primary and recurrent glioblastoma.

Authors:  Maryam Rahman; Jesse Kresak; Changlin Yang; Jianping Huang; Wesley Hiser; Paul Kubilis; Duane Mitchell
Journal:  J Neurooncol       Date:  2018-01-04       Impact factor: 4.130

7.  Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas.

Authors:  Agustí Alentorn; Caroline Dehais; François Ducray; Catherine Carpentier; Karima Mokhtari; Dominique Figarella-Branger; Olivier Chinot; Elisabeth Cohen-Moyal; Carole Ramirez; Hugues Loiseau; Selma Elouahdani-Hamdi; Patrick Beauchesne; Olivier Langlois; Christine Desenclos; Jean-Sébastien Guillamo; Phong Dam-Hieu; François Ghiringhelli; Philippe Colin; Joel Godard; Fabrice Parker; Frédéric Dhermain; Antoine F Carpentier; Jean-Sebastien Frenel; Philippe Menei; Luc Bauchet; Thierry Faillot; Mélanie Fesneau; Denys Fontaine; Marie-Jeannette Motuo-Fotso; Elodie Vauleon; Claude Gaultier; Caroline Le Guerinel; Edouard-Marcel Gueye; Georges Noel; Nicolas Desse; Xavier Durando; Eduardo Barrascout; Michel Wager; Damien Ricard; Ioana Carpiuc; Jean-Yves Delattre; Ahmed Idbaih
Journal:  Neurology       Date:  2015-09-18       Impact factor: 9.910

8.  Extracranial oral cavity metastasis from glioblastoma multiforme: A case report.

Authors:  Philipp Günther Kup; Carsten Nieder; Guido Winnekendonk; Irenäus Anton Adamietz; Khashayar Fakhrian
Journal:  Mol Clin Oncol       Date:  2016-08-12

9.  A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel.

Authors:  Patrick J Cimino; Andy Bredemeyer; Haley J Abel; Eric J Duncavage
Journal:  Exp Mol Pathol       Date:  2015-04-22       Impact factor: 3.362

10.  A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma.

Authors:  Jezabel Rodriguez-Blanco; Bin Li; Jun Long; Chen Shen; Fan Yang; Darren Orton; Sara Collins; Noriyuki Kasahara; Nagi G Ayad; Heather J McCrea; Martine F Roussel; William A Weiss; Anthony J Capobianco; David J Robbins
Journal:  Clin Cancer Res       Date:  2018-11-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.